Latest Interim Results News

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

Terrain Minerals is progressing metallurgical studies on its Larin’s Lane Gallium and Rare Earth Elements project, aiming to develop sustainable extraction methods and expand resource potential. Concurrently, the company has launched a $1.8 million rights issue to fund ongoing exploration and development.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.

Westpac Banking Corporation reported a slight 1% decline in net profit to $3.3 billion for the first half of 2025, while business and institutional lending grew robustly. The bank maintained a solid capital position and announced a fully franked interim dividend of 76 cents per share.

Westpac Banking Corporation posted a $3.5 billion net profit for the first half of 2025, maintaining strong capital ratios and advancing its digital transformation and sustainability initiatives despite a slight earnings dip.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

Kinetiko Energy reports encouraging progress in South African gas exploration, with improved well performance and a drilling optimisation study revealing key production enhancements.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.